TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00763412
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
Study: NCT04602013
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)
Study: NCT00657540
Drug: Analatro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
Study: NCT00001917
Drug: [F-18] FP-TZTP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03013504
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 via i.v. infusion during cycles 5-8.
Study: NCT00092781
Drug: MK0663, etoricoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00092781
Drug: Comparator: celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00628862
Drug: Turbuhaler® placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo inhaled twice daily
Study: NCT04115384
Drug: Novolin-R insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril), twice per day, once in the morning and again in the evening (at least 8 hours between doses) for 4 weeks.
Study: NCT01271517
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar
Study: NCT00176774
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
Study: NCT00964496
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
Study: NCT02171507
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02305030
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03185156
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump
Study: NCT01318421
Drug: ELND002
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02976337
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT01255423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 4 times daily
Study: NCT00988598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days
Study: NCT00231777
Drug: Comparator: MK0517
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single administration of 40 mg MK0517 by IV immediately prior to surgery
Study: NCT01612975
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
Study: NCT01612975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
Study: NCT00160186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02675309
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02675309
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02726620
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT02726620
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT02726620
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT02726620
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid used to treat intraoperative hypotension
Study: NCT02726620
Drug: Fresh Frozen Plasma
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid used to treat intraoperative hypotension
Study: NCT02726620
Drug: Packed Red Blood Cells
Normalized name: Packed red blood cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid used to treat intraoperative hypotension
Study: NCT02726620
Drug: Plasma-Lyte
Normalized name: Plasma-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid used to treat intraoperative hypotension
Study: NCT02726620
Drug: Benzocaine
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic used for central neuraxial anesthesia.
Study: NCT02136316
Drug: ASP7962
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02136316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00673218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
Study: NCT00003815
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003815
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01365208
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: platinum-based chemotherapy
Study: NCT00003815
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02462148
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used in nerve block mixture
Study: NCT04503746
Drug: ALH-L1005 600mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALH-L1005 300mg 2 tablet and placebo 2 tablet
Study: NCT04503746
Drug: ALH-L1005 1,200mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALH-L1005 300mg 4 tablet
Study: NCT00257348
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04503746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 4 tablet
Study: NCT01904409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03986996
Drug: amoxicillin, metronidazole and doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotics: Patient weight 30-50 kg Patient weight \> 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks Metronidazole 250 mg X 2 Day X 2 weeks 375 mg X 2 Day X 2 weeks
Study: NCT01308736
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
Study: NCT00634439
Drug: Stimulants
Normalized name: CNS STIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate, amphetamines (including Adderall and mixed salts)
Study: NCT01379183
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg suspension
Study: NCT01379183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg suspension
Study: NCT00259714
Drug: standard dialysate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prescribed dialysate sodium is 140 mEq/L
Study: NCT03723811
Drug: SJP002 BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop b.i.d for 12 weeks
Study: NCT03723811
Drug: SJP002 QID
Normalized name: MINOXIDIL 5 g in 100 mL / BIOTIN 5 g in 100 mL EXTRACORPOREAL AEROSOL, FOAM [QIDILA 5% Minoxidil Foam]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop q.i.d for 12 weeks
Study: NCT03723811
Drug: SJP002 Placebo 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop q.i.d for 12 weeks
Study: NCT03723811
Drug: SJP002 Placebo 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop q.i.d for 12 weeks
Study: NCT04152226
Drug: J. Lividum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product
Study: NCT00337545
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00131144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02867735
Drug: LKA651
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional
Study: NCT02414308
Drug: Adipose tissue stem cell injection
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
Study: NCT00646646
Drug: saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline placebo
Study: NCT01067677
Drug: Metaclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg for rescue after PONV
Study: NCT00549848
Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description section for details of treatment interventions.
Study: NCT02161796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00240058
Drug: Regional phenylephrine arterial infusion, Nitric Oxide Clamp
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03918616
Drug: Memantine, Dopamine receptor-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study do not provide any experimental drugs. Patientes will receive treatment routinary used by Neurologist for these diseases.
Study: NCT02327611
Drug: Custodiol
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02327611
Drug: Enriched Ringer's lactate solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02135042
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01089751
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily on an empty stomach for 14 weeks.
Study: NCT03990272
Drug: placebo drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day
Study: NCT03959241
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. Methotrexate should be dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per institutional guidelines.
Study: NCT00976131
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care chemotherapy medication used to treat cancer.
Study: NCT00976131
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care chemotherapy medication used to treat cancer.
Study: NCT03959241
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if actual body weight (ABW) \< IBW, use ABW\] will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
Study: NCT00629941
Drug: AzaSite®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Study: NCT04508946
Drug: vitamin c - thiamine- hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy regimen (vitamin c - thiamine- hydrocortisone)
Study: NCT01402440
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03593213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules, oral administration, once daily.
Study: NCT01023490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01425801
Drug: LAS100977 0.313 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder inhalation, once-daily, single-dose
Study: NCT01425801
Drug: LAS100977 0.625 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder inhalation, once-daily, single-dose
Study: NCT01425801
Drug: LAS100977 1.25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder inhalation, once-daily, single-dose
Study: NCT01425801
Drug: LAS100977 2.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder inhalation, once-daily, single-dose
Study: NCT01425801
Drug: Salbutamol 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized inhalation suspension, once-daily, single-dose
Study: NCT01425801
Drug: Salbutamol placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized inhalation, once-daily
Study: NCT01425801
Drug: LAS100977 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder inhalation, once-daily
Study: NCT03260179
Drug: AL3810
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting，oral ，4w on or 3w on/1w off
Study: NCT03702673
Drug: K-877 CR Tablet B
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 Controlled Release Tablet B
Study: NCT03702673
Drug: K-877 CR Tablet E
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 Controlled Release Tablet E
Study: NCT00001944
Drug: XR9576
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03702673
Drug: K-877 IR Tablet
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 Immediate Release Tablet
Study: NCT00494780
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
Study: NCT00494780
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
Study: NCT00532220
Drug: Ibandronate IV
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
Study: NCT00532220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
Study: NCT01254019
Drug: GSK2402968 6mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous
Study: NCT04480268
Drug: PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PAXG regimen includes:~* nab-paclitaxel 150 mg/m2 on day 1 and 15 of each cycle;~* cisplatin 30 mg/m2 on day 1 and 15 of each cycle;~* capecitabine 1250 mg/m2 on 1 day to 28 of each cycle;~* gemcitabine 800 mg/m2 on day 1 and 15 of each cycle. Each cycle lasts 28 days. Patients are treated until maximal response, disease progression or unacceptable toxicity.
Study: NCT04563559
Drug: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Normalized name: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule
Study: NCT00781196
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule 0.5 mg once a day
Study: NCT00781196
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, once a day
Study: NCT00311766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
Study: NCT04582786
Drug: STR-324
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of solution for intravenous administration
Study: NCT01147341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: prefilled saline syringe
Study: NCT01157182
Drug: Estradiol/Norethindrone acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/0.5 mg Tablets
Study: NCT01157182
Drug: Activella®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/0.5 mg Tablets
Study: NCT00398606
Drug: Comparator : calcium carbonate /Duration of Treatment : 2 Years
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02888080
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.
Study: NCT02888080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.
Study: NCT00872235
Drug: fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets
Normalized name: Quinapril and Hydrochlorothiazide Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03169335
Drug: QL1101
Approvals — FDA: no, EMA: no, PMDA: no
Description: targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
Study: NCT03169335
Drug: Avastin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
Study: NCT04439799
Drug: Intranasal Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant in this group will receive Intranasal testosterone administered using a multi-dose dispenser, as two or three daily doses (5.5 mg per nostril, 11.0 mg single dose) for 4 consecutive months,
Study: NCT02076451
Drug: DS-8273a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks
Study: NCT02878330
Drug: MEDI8897
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single IM dose of 50 mg on Day 1 of the study.
Study: NCT02878330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.
Study: NCT02641990
Drug: ITCA 650 20/60 mcg/day, ITCA placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days
Study: NCT02641990
Drug: ITCA placebo, ITCA 650 20/60 mcg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
Study: NCT03375034
Drug: NDMC 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of one NDMC 20mg capsule and two Placebo capsules
Study: NCT03375034
Drug: NDMC60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of three NDMC 20mg capsules
Study: NCT03375034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of three Placebo capsules
Study: NCT01039688
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered at a dose of 5 mg BID for 24 months
Study: NCT00668863
Drug: FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT01065220
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 microgram TTS twice a week
Study: NCT01065220
Drug: 5-alpha reductase inhibitor
Normalized name: 5-alpha reductase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg daily
Study: NCT03301025
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: given a placebo identical capsule once one hour before anesthesia
Study: NCT04102462
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT00482378
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg by IV monthly.